Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study.

Medicina (Kaunas) · 2025 · PMC12299443 · PMID 40731782

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

did not reach statistical significancep = 0.059so close (0.05 < p ≤ 0.1)

Although a reduction in fat mass was also observed in the non-SGLT2i group (from 30.4 ± 11.1 kg to 28.0 ± 8.3 kg), this change did not reach statistical significance ( p = 0.059).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.